The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Glenn J HannaJi Eun BaeJochen H LorchRobert I HaddadVickie Y JoJonathan D SchoenfeldDanielle N MargalitRoy B TishlerLaura A GoguenDonald J AnninoNicole G ChauPublished in: The oncologist (2020)
Results of this study showed an improved disease-free and overall survival in patients treated with adjuvant trastuzumab for high-risk salivary gland cancers with strong HER-2/neu staining intensity. Following recurrence or metastatic spread, sequential HER-2, and androgen-directed therapies may benefit certain patients with salivary gland cancer.